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patients with both negative tests - 6 months. These data suggest that 
EGFR protein expression, alone or with other markers, may be useful 
predictor of sensitivity to EGFR TKIs and that EGFR negative patients 
by immunohistochemistry are unlikely to beneﬁt from these drugs. The 
value of EGFR protein expression for patient selection to the ﬁrst-line 
and adjuvant treatments is currently tested in several clinical studies in 
enriched populations (e.g. RADIANT adjuvant trial with erlotinib).
Activated EGFR (p-EGFR) as well as several downstream signaling 
proteins (p-Akt, p-MAPK, p-STAT3) and epithelial-to-mesenchymal 
transition markers (E-cadherin, vimentin) were studied in relation to 
sensitivity to EGFR TKIs in vitro as well as in clinical samples. P-Akt 
positivity was associated with improved response rate and time to pro-
gression in one retrospective study (12), but molecular analysis of the 
ISEL trial with geﬁtinib did not conﬁrm this ﬁnding (6). At present, we 
have insufﬁcient data to use these markers as predictors of sensitivity to 
EGFR inhibitors in practice.
Data on protein expression and the outcome of patients treated with 
anti-EGFR monoclonal antibodies are scarce. Most of the studies with 
cetuximab enrolled NSCLC patients with EGFR protein-positive tu-
mors, and therefore it is impossible to assess the value of EGFR status 
on study outcome. 
Tumor heterogeneity, differences between surgical versus bronchos-
copy specimens or primary versus metastatic tumors may account for 
variations that should be recognized when using immunohistochemistry 
for patient selection. Different antibodies and grading systems should 
also be taken into account. Counting of positive tumor cells and grad-
ing of staining intensity may be a subject of interobserver variability, 
which should be evaluated. Automated scoring systems are available, 
but comparison studies with light microscopy and conventional scoring 
are needed prior to their wide-spread use. 
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Introduction
Early detection of central type lesions, especially intraepithelial stage, 
is a challenge for bronchoscopists. Last decade has witnessed several 
advances in both technical and clinical aspects of bronchology. These 
advances have led to better diagnostic yield from bronchoscopy. 
Fiberoptic bronchoscope has been replaced by videoendoscope, so 
bronchoscopists can capture more detailed images of the bronchus. 
Inhaled carcinogens may cause cumulative genetic damage to the entire 
bronchial surface resulting in genetic disorder. The multicentric nature 
of central type lung cancer may be the result of ﬁeld cancerization. 
This theory also supports the concept of multistep carcinogenesis: lung 
cancer developing through a series of morphological changes from dys-
plasia to carcinoma in situ and then invasive cancer. The Lung Cancer 
Screening Study at Johns Hopkins found that moderate dysplasia in 
sputum may result in a 10% future incidence of lung cancer and 40% of 
severe dysplasia results in future cancer development (1). The detection 
of dysplastic lesions are also encouraged because they are regarded 
as precancerous lesions. However, dysplasias are generally a few cell 
layers thick and are detected only by chance. Autoﬂuorescence bron-
choscopy (AFB) has widely spread since early 1990’s. Several studies 
have shown that AFB improved the sensitivity of cancer and dysplastic 
lesions of the airway, especially those in intraepithelial stage (2-10). 
Recently, videoendoscopy-based autoﬂuorescence systems have come 
into clinical use (9,10). Synchronous dual images with white light and 
AFB with better resolution than that of ﬁberscopy-based AFB could be 
obtained. (10)
Patients
There is as yet no universally accepted indication as to who should 
undergo AFB. Indications need to be established based on the consider-
ation of beneﬁt and risk of this procedure.
Usually, cases for AFB are classiﬁed into 4 groups as described below.
Patients with known or suspected lung cancer who were scheduled for 
bronchoscopy as a part of standard examination.
Patients with abnormal sputum cytology ﬁndings (moderate atypia or 
worse) with a normal chest radiograph.
Patients after curative surgery of stage I lung cancer who were sched-
uled for bronchoscopy as a part of follow up.
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Heavy smokers with respiratory symptom.
Videoendoscopy-based AFB
The system used was color CCD videoendoscopy based AF system. 
It has two light sources available; one is a Xenon lamp for white light 
image and the other is a diode laser which works as AFB mode excita-
tion light source. Infra-red light is eliminated by an Infra Red cut ﬁlter 
and white light is collected by the lens and transmitted to the objects 
through the light guide of the videoendoscope. In AFB mode, the ex-
citation light is on and is reﬂected by a beam splitter and collected and 
transmitted by the light guide. Excitation light is shone on the objects 
from the tip of the scope. The objective lens functions to eliminate the 
wavelength of excitation light and captures only AFB from the object 
(10). 
Results
A total of 257 high risk patients for lung cancer received AFB and 306 
biospy specimens from suspected areas were evaluated by experienced 
pathologists. Invasive cancers were equally diagnosed by both video-
endoscopy and AFB. AFB could diagnose all of 33 CIS lesions, while 
4 lesions could not be detected by white light. AFB diagnosed 60 of 67 
(90%) dysplastic lesions, while white light diagnosed 41 of 67 (61%). 
Discussion
Most studies in the past reported increased sensitivity of dysplasia or 
cancer in patients at high risk by autoﬂuorescence bronchoscopy com-
pared to white light alone (2-10).
However, morphological classiﬁcation of grades of dysplasias in 
objective way as well as the follow up protocol of high grade dysplasia 
should be discussed (11). Genetic anaysis and quantitative pathology 
may bring a clue of this problem. Also, optical biopsy of (endoscopic 
histological diagnosis without obtaining tissue sample) of dysplasia 
would be possible using optical coherence tomography in near future.
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Computed tomography (CT) scanning for various reasons be it abdo-
men symptoms, assessment of the coronary arteries or in screening 
for lung cancer will identify a large percentage of patients with one or 
more lung nodules. What constitutes a ditzel on CT? Neither Miriam-
Webster’s nor Stedman’s dictionaries deﬁne ditzel, but colloquial use 
suggests that it is an object of small stature that is of little consequence. 
The size of a ditzel not deﬁned, but for the sake of this discussion I 
will use a somewhat arbitrary distinction of a nodule of ≤ 5 mm that is 
non-calciﬁed. A nodule of this size has a low-but not no-likelihood of 
being a cancer. Nodules of this size are essentially not seen on chest 
radiographs unless they are calciﬁed. Larger sized nodules will not be 
addressed in this discussion. 
The results of prospective single-arm, observational studies in various 
countries show that rates of nodule detection at baseline screening 
ranges from 20-50% in participants at high risk for lung cancer. 1-6 The 
frequency of nodule detection has been demonstrated to be a function 
of CT slice thickness (collimation). Studies using 10 mm collimation 
have reported one or more nodules detected in about 25% of the partici-
pants. 1-3 Studies using 5 mm collimation ﬁnd one or more nodules 
in about 50% of the participants. 4-6 In a Vancouver study the nodules 
detection rate was 36% at 7mm collimation and increased to 60% when 
1.25 mm collimation was used. 6 In contrast, the rate of non-calciﬁed 
nodule detection at annual repeat scanning is less, in the range of 3-
18%. 2,3,7-9 Needless to say, CT screening frequently requires decisions 
regarding nodule management. At present, the optimal nodule manage-
ment of nodules of various sizes and character is in evolution. 
As cancer growth is a time-based principle, earlier implies smaller. 
The desire to detect small cancers is made problematic by the poten-
tial number of small benign lesions from which the malignant ones 
require identiﬁcation. Herein lies the crux of the problem presented to 
the clinician or researcher evaluating the patient or participant who has 
had a CT and one or more nodules are found. Optimal evaluation of 
screen-detected lesions identiﬁes cancer with haste and avoids resection 
of benign lesions. If the evolving technologic advance of CT leads to 
smaller and smaller malignancies, this may be of beneﬁt to the patient-
as a consequence, it would appear that the detection of more nodules 
and therefore an increasing number of false-positives may well be the 
good news rather than the bad news. 
The concern over high false-positive rates has led some authors to 
change the deﬁnition of a positive scan by considering noncalciﬁed 
nodules that are less that 5 mm as negative. This does serve to reduce 
the number of false-positive scans, but unfortunately, some of these 
small nodules are malignant and also one increases the rate of false-
negative scans. In the ELCAP study, 1% of the nodules detected at 2-5 
mm were malignant. 1 In the Mayo study, Swensen reported that 5 of 
40 lung cancers identiﬁed were less than 5 mm in diameter at initial 
detection. 9 McWilliams reported that 18% of the cancers identiﬁed by 
CT screening were detected when less than 4 mm. 10 The ideal screen-
ing study would have a zero false-negative rate. If we, by convention, 
determine that nodules of a few millimeters in size are to be considered 
negative, we enhance the likelihood of false-negative scans. This is 
borne out in an Italian study in which non-calciﬁed nodules of 5 mm 
or less in maximal diameter considered as negative. 3 Annual repeat 
scanning identiﬁed 11 cancers, and 6 of these were classiﬁed as benign 
